Home > Dermatology > AAD 2019 > JAK Inhibitors: A New Frontier in Dermatology > JAK inhibitors: a pathogenesis-directed therapy for alopecia areata

JAK inhibitors: a pathogenesis-directed therapy for alopecia areata

Presented By
Prof. Brittany Craiglow, Yale University School of Medicine, USA
AAD 2019

Preliminary data has shown that JAK inhibitors could represent a promising novel way to treat alopecia areata (AA), a non-scarring alopecia, which affects about 1-2% of the population.

Most commonly it presents as round patches of alopecia. “AA is not cosmetic; it is something we have to treat because it is frequently emotionally devastating,” said Prof. Brittany Craiglow (Yale University School of Medicine, USA) [1]. A review including 11 trials with data from 1,986 patients with AA demonstrated that patients have a really low health-related quality of life (HRQoL), which is similar to patients with atopic dermatitis or psoriasis [2]. Before medical therapy is started, HRQoL and psychosocial functioning should be evaluated in every patient.

Up to now, there were no reliably, effective treatments, especially for advanced disease. Topical, intralesional, and systemic corticosteroids were the mainstay of treatment. Research using human clinical sample...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on